Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 3 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Cellectis currently manages a patent portfolio containing 6 pending office actions within the Biotechnology & Pharmaceuticals technology area. These pending matters are distributed across 6 distinct examiners, which indicates that each individual action is being reviewed by a different examiner at the patent office. This direct ratio between pending actions and examiners suggests a diverse range of technical subject matter that requires specialized review from multiple points of contact.
The prosecution activity for Cellectis spans 4 distinct art units, showing a concentration of technical focus despite the variety of examiners involved. KIM, TAEYOON is identified as the busiest examiner for the portfolio, currently responsible for 1 pending office action. Because the busiest examiner's load of 1 matches the load of every other examiner in the portfolio, the 6 pending office actions are distributed across the 6 distinct examiners. This decentralized prosecution environment across 4 distinct art units requires the company to manage multiple examiner relationships simultaneously.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 4 (80%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIM, TAEYOON | 1 | 51.4% | +52.2% |
| COLLINS, CYNTHIA E | 1 | 82.2% | +9.0% |
| BRISTOL, LYNN ANNE | 1 | 63.4% | +39.8% |
| NGUYEN, QUANG | 1 | 37.9% | +52.6% |
| ZHONG, WAYNESHAOBIN | 1 | 72.3% | +21.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18737469 | METHODS FOR NON-TRANSGENIC GENOME EDITING IN PLANTS | COLLINS, CYNTHIA E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18297770 | CANOLA WITH HIGH OLEIC ACID | ZHONG, WAYNESHAOBIN | 60d overdue |
| 18914680 | CELLULAR IMMUNOTHERAPY FOR REPETITIVE ADMINISTRATION | KIM, TAEYOON | — |
| 18607387 | INHIBITORY CHIMERIC ANTIGEN RECEPTORS | BRISTOL, LYNN ANNE | — |
| 18530878 | METHODS FOR ENGINEERING ALLOGENEIC AND IMMUNOSUPPRESSIVE RESISTANT T CELL FOR IMMUNOTHERAPY | NGUYEN, QUANG | — |
| Art Unit | Apps |
|---|---|
| 1631 | 2 |
| 1662 | 2 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18914680 | CELLULAR IMMUNOTHERAPY FOR REPETITIVE ADMINISTRATION | KIM, TAEYOON | 1631 | §103§112DP | Non-Final OA | — | Pending | Oct 14, 2024 |
| 18737469 | METHODS FOR NON-TRANSGENIC GENOME EDITING IN PLANTS | COLLINS, CYNTHIA E | 1662 | §103§112 | Non-Final OA | — | Pending | Jun 07, 2024 |
| 18607387 | INHIBITORY CHIMERIC ANTIGEN RECEPTORS | BRISTOL, LYNN ANNE | 1643 | §112DP | Non-Final OA | — | Pending | Mar 15, 2024 |
| 18530878 | METHODS FOR ENGINEERING ALLOGENEIC AND IMMUNOSUPPRESSIVE RESISTANT T CELL FOR IMMUNOTHERAPY | NGUYEN, QUANG | 1631 | §102§103§112DP | Non-Final OA | — | Pending | Dec 06, 2023 |
| 18297770 | CANOLA WITH HIGH OLEIC ACID | ZHONG, WAYNESHAOBIN | 1662 | §102§103§112DP | Final Rejection | 60d overdue | Pending | Apr 10, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCellectis has 5 pending office actions as of October 2026, spread across 3 art units and 5 examiners.
Taeyoon Kim has the most, with 1 of Cellectis's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
